Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases

Giuseppe Procopio, Elena Verzoni, Pamela Biondani, Paolo Grassi, Isabella Testa, Enrico Garanzini, Filippo De Braud

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences